Clinical Trial: Donidalorsen Treatment in Children With Hereditary Angioedema

U.S., Dec. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07298447) titled 'Donidalorsen Treatment in Children With Hereditary Angioedema' on Dec. 19.

Brief Summary: The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of donidalorsen in pediatric participants with hereditary angioedema (HAE) Type I (HAE-1) or Type II (HAE-2).

Study Start Date: Jan., 2026

Study Type: INTERVENTIONAL

Condition: Hereditary Angioedema (HAE)

Intervention: DRUG: Donidalorsen

Donidalorsen will be administered by subcutaneous (SC) injection.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Ionis Pharmaceuticals, Inc.

Disclaimer: Curated by HT Syndication....